The Star Tribune published an article on the local state of medical technology investment capital in the age of inflation.
2021 set a new record for healthcare industry investments in the US and Europe, but as this year’s interest rates increase, supply chains breakdown, prices soar, and markets tumble, the flow of investment cash has reduced by roughly 25%.
To get perspective on what this means for the local economy, the Star Tribune reached out to our CEO, Danny Cunagin. Even though the bar has been raised for investment criteria, Cunagin is still excited for intelligent teams that have a great product.
Cunagin went on to share the investment goals of Invenshure’s newest company, MEKanistic Therapeutics. On track to securing $5 million from their investor network this year, he did admit his next year’s goal of finding between $30M-$40M for Phase 1 clinical trials will be met with greater scrutiny; they want to see bulletproof pitches from company founders.
"I think that your fundamentals have to be really solid, your team has to be really solid," Cunagin said.
To read the full article, visit the Star Tribune.
To learn more about the technology being incubated at Invenshure, connect with Adam Becker at adambecker@invenshure.com or by calling 612.200.3080.